Lymphoma News

Rituximab-Based Immunotherapy May Be As Effective as Chemotherapy in Follicular Lymphoma

Rituximab-Based Immunotherapy May Be As Effective as Chemotherapy in Follicular Lymphoma

Rituximab plus lenalidomide immunotherapy may be an effective alternative to chemotherapy for patients with follicular lymphoma.

FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma

FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma

Mogamulizumab-kpkc (Poteligeo), a humanized monoclonal antibody that targets CCR4, provides a new treatment option for patients with MF and is the first FDA-approved therapy for SS.

Preliminary Topline Results for Tislelizumab in Classical Hodgkin Lymphoma

Preliminary Topline Results for Tislelizumab in Classical Hodgkin Lymphoma

A pivotal phase 2 trial indicates promise for another checkpoint drug, this time for patients with classical Hodgkin lymphoma.

Combined Modality Therapy May Be More Effective Than Radiotherapy Alone in Follicular Lymphoma

Combined Modality Therapy May Be More Effective Than Radiotherapy Alone in Follicular Lymphoma

Evidence from previous studies have demonstrated that combined modality therapy with chemotherapy and radiotherapy may improve long-term outcomes in this patient population.

Rituximab Plus Lenalidomide As First-Line Treatment May Be Effective in Follicular Lymphoma

Rituximab Plus Lenalidomide As First-Line Treatment May Be Effective in Follicular Lymphoma

Researchers randomly assigned 1030 patients with grade 1 to 3a follicular lymphoma to receive lenalidomide plus rituximab or rituximab plus investigator's choice chemotherapy of CHOP, CVP, or bendamustine.

Small Study Shows Curative Benefit of Allogeneic Hematopoietic Cell Transplantation Mantle Cell Lymphoma

Small Study Shows Curative Benefit of Allogeneic Hematopoietic Cell Transplantation Mantle Cell Lymphoma

Moffitt Cancer Center investigators believe allo-HCT may actually be "curative" for patients with a certain type of lymphoma.

R-THP-COP a New Therapeutic Alternative for Diffuse Large B-Cell Lymphoma

R-THP-COP a New Therapeutic Alternative for Diffuse Large B-Cell Lymphoma

Results of a prospective phase 3 study demonstrated noninferiority of R-THP-COP for diffuse large B cell lymphoma to the standard of care, suggesting the regimen may be an alternative option for these patients.

JAK1/2 Inhibition in Myelofibrosis Linked to Increased Risk for Aggressive B-Cell Lymphomas

JAK1/2 Inhibition in Myelofibrosis Linked to Increased Risk for Aggressive B-Cell Lymphomas

While JAK 1/2 inhibitors are effective at reducing symptoms of myelofibrosis, several cases of sporadic B-cell non-Hodgkin lymphomas have been reported in treated patients.

Lenalidomide Plus Rituximab May Be As Effective As Standard of Care in Follicular Lymphoma

Lenalidomide Plus Rituximab May Be As Effective As Standard of Care in Follicular Lymphoma

Previous studies have shown that rituximab plus lenalidomide may not only be as effective but also improve immune competence in this patient population.

Interim PET Scans May Predict Survival Outcomes in Non-Hodgkin Lymphoma

Interim PET Scans May Predict Survival Outcomes in Non-Hodgkin Lymphoma

Being able to identify which patients would respond to standard therapies allows for early adjustment in treatment and improves outcomes.

Rituximab, Gemcitabine, Plus Oxaliplatin May Be an Effective First-Line Option in Elderly DLBCL

Rituximab, Gemcitabine, Plus Oxaliplatin May Be an Effective First-Line Option in Elderly DLBCL

Rituximab, gemcitabine, plus oxaliplatin has shown high efficacy with low toxicity among elderly patients with relapsed/refractory diffuse large b-cell lymphoma in previous studies.

FDA Expands Tisagenlecleucel Indication To Include Relapsed/Refractory B-cell Lymphomas

FDA Expands Tisagenlecleucel Indication To Include Relapsed/Refractory B-cell Lymphomas

The FDA based its approval on results of the single-arm phase 2 JULIET clinical trial.

Ixazomib, Dexamethasone, and Rituximab: Promising for Waldenström Macroglobulinemia

Ixazomib, Dexamethasone, and Rituximab: Promising for Waldenström Macroglobulinemia

The median progression-free survival was not reached after a median follow-up of 22 months.

Lenalidomide: Feasible for Patients With Relapsed, Refractory MCL

Lenalidomide: Feasible for Patients With Relapsed, Refractory MCL

At time of analysis, 14 of the 22 complete responses were ongoing.

Evaluating the Relationship Between Q Fever and Non-Hodgkin Lymphoma

Evaluating the Relationship Between Q Fever and Non-Hodgkin Lymphoma

Findings from a previous study suggested that Q fever may significantly increase a person's risk of nHL.

Tazemetostat Active in Non-Hodgkin Lymphomas, Solid Tumors

Tazemetostat Active in Non-Hodgkin Lymphomas, Solid Tumors

The recommended phase 2 dose is 800 mg twice daily.

FDA Grants Priority Review to Duvelisib for CLL/SLL and Follicular Lymphoma

FDA Grants Priority Review to Duvelisib for CLL/SLL and Follicular Lymphoma

The FDA is reviewing a New Drug Application, which is requesting full approval for CLL/SLL and accelerated approval for follicular lymphoma.

Obinutuzumab Plus Bendamustine Prolongs PFS in Rituximab-Refractory Non-Hodgkin Lymphoma

Obinutuzumab Plus Bendamustine Prolongs PFS in Rituximab-Refractory Non-Hodgkin Lymphoma

Previous findings showed that patients obinutuzumab plus bendamustine prolonged progression-free survival, but data was immature at the time of analysis.

Ibrutinib Plus Venetoclax Significantly Improves Complete Response Rate in Mantle Cell Lymphoma

Ibrutinib Plus Venetoclax Significantly Improves Complete Response Rate in Mantle Cell Lymphoma

Preclinical models predict that ibrutinib and venetoclax would have a synergistic effect in dual inhibition for mantle cell lymphoma.

FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma

FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma

This marks the fifth FDA-approved indication for brentuximab vedotin and the first approval for front-line stage III or IV CHL in more than 4 decades.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Cancer Therapy Advisor Articles